Generation of recombinant skin in vitro by adeno-associated virus type 2 vector transduction

被引:15
作者
Agrawal, N
You, H
Liu, Y
Chiriva-Internati, M
Bremner, J
Garg, T
Grizzi, F
Prasad, CK
Mehta, JL
Hermonat, PL
机构
[1] Univ Arkansas Med Sci, Dept Obstet & Gynecol, Little Rock, AR 72205 USA
[2] Univ Arkansas Med Sci, Dept Internal Med, Gene Therapy Program, Little Rock, AR 72205 USA
[3] Texas Tech Univ, Dept Microbiol & Immunol, Lubbock, TX 79409 USA
[4] Univ Sheffield, Div Genom Med, Sheffield, S Yorkshire, England
[5] Inst Clin Humanitas, Sci Direct, Milan, Italy
来源
TISSUE ENGINEERING | 2004年 / 10卷 / 11-12期
关键词
D O I
10.1089/ten.2004.10.1707
中图分类号
Q813 [细胞工程];
学科分类号
摘要
It has long been recognized that skin may be a particularly good target for pharmacologic gene therapy and as a platform for the secretion of systemically distributed molecules. Adeno-associated virus type 2 (AAV) is a useful vector for skin gene therapy because skin is the natural host tissue for AAV, in which it functions as an autonomous parvovirus. We demonstrate here that recombinant (r) AAV vectors carrying the granulocyte-macrophage colony-stimulating factor (GM-CSF), human papillomavirus E6, or green fluorescent protein (GFP) transgene could transduce primary human keratinocytes in ex vivo culture. We further demonstrate that these transduced cells could be used to form a transgene-positive recombinant skin (r-skin), using the organotypic epithelial raft culture system. Transduction of keratinocytes was demonstrated by reverse transcriptase-polymerase chain reaction (RT-PCR) for RNA expression, enzyme-linked immunosorbent assay (ELISA) for product secretion, intracellular staining for protein expression, vector-chromosomal junction PCR and Southern blot analysis of proviral sequences, in situ immunohistochemistry analysis of protein expression, and ultraviolet light fluorescence for GFP expression. AAV/GM-CSF/Neo-infected keratinocyte/raft skins secreted GM-CSF at levels as high as 25 ng/cm(2) of skin and maintained expression to 60 days postinfection. These data support the utility and efficiency of AAV-based gene delivery to produce genetically altered keratinocytes and r-skin.
引用
收藏
页码:1707 / 1715
页数:9
相关论文
共 46 条
[1]   Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column [J].
Auricchio, A ;
Hildinger, M ;
O'Connor, E ;
Gao, GP ;
Wilson, JM .
HUMAN GENE THERAPY, 2001, 12 (01) :71-76
[2]   CHARACTERIZATION OF THE DNA OF A DEFECTIVE HUMAN PARVOVIRUS ISOLATED FROM A GENITAL SITE [J].
BANTELSCHAAL, U ;
HAUSEN, HZ .
VIROLOGY, 1984, 134 (01) :52-63
[3]   ISOLATION OF ADENOVIRUS-ASSOCIATED VIRUSES FROM MAN [J].
BLACKLOW, NR ;
HOGGAN, MD ;
ROWE, WP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1967, 58 (04) :1410-&
[4]   Hematopoietic colony-stimulating factors for neutropenic patients in the ICU [J].
Bouchama, A ;
Khan, B ;
Djazmati, W ;
Shukri, K .
INTENSIVE CARE MEDICINE, 1999, 25 (09) :1003-1005
[5]   Efficient gene transfer into human keratinocytes with recombinant adeno-associated virus vectors [J].
Braun-Falco, M ;
Doenecke, A ;
Smola, H ;
Hallek, M .
GENE THERAPY, 1999, 6 (03) :432-441
[6]   GM-CSF ACTIVATES REGENERATIVE EPIDERMAL GROWTH AND STIMULATES KERATINOCYTE PROLIFERATION IN HUMAN SKIN IN-VIVO [J].
BRAUNSTEIN, S ;
KAPLAN, G ;
GOTTLIEB, AB ;
SCHWARTZ, M ;
WALSH, G ;
ABALOS, RM ;
FAJARDO, TT ;
GUIDO, LS ;
KRUEGER, JG .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1994, 103 (04) :601-604
[7]   A randomized, controlled trial of prophylactic granulocyte-macrophage colony-stimulating factor in human newborns less than 32 weeks gestation [J].
Carr, R ;
Modi, N ;
Doré, CJ ;
El-Rifai, R ;
Lindo, D .
PEDIATRICS, 1999, 103 (04) :796-802
[8]   LACK OF EXPRESSION FROM A RETROVIRAL VECTOR AFTER TRANSDUCTION OF MURINE HEMATOPOIETIC STEM-CELLS IS ASSOCIATED WITH METHYLATION IN-VIVO [J].
CHALLITA, PM ;
KOHN, DB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (07) :2567-2571
[9]  
Chiriva-Internati M, 2002, EUR J IMMUNOL, V32, P30, DOI 10.1002/1521-4141(200201)32:1<30::AID-IMMU30>3.0.CO
[10]  
2-E